Search results
Results from the WOW.Com Content Network
The risk of first-degree relatives developing the same hypersensitivity reaction is higher than in the general population. [ 1 ] As this syndrome can present secondary to multiple anticonvulsants, the general term "anticonvulsant hypersensitivity syndrome" (AHS) is favored over the original descriptive term "dilantin hypersensitivity syndrome."
The types of adverse reactions that should be reported are: Those that have caused death or a serious illness; Any adverse reaction, however minor, if associated with a new medicine or one that is under continued monitoring (highlighted in the British National Formulary with a black triangle)
Type A: augmented pharmacological effects, which are dose-dependent and predictable [5]; Type A reactions, which constitute approximately 80% of adverse drug reactions, are usually a consequence of the drug's primary pharmacological effect (e.g., bleeding when using the anticoagulant warfarin) or a low therapeutic index of the drug (e.g., nausea from digoxin), and they are therefore predictable.
CDR is one means of establishing the validity and benefits of medication in treating specific conditions [1] as well as any adverse drug reactions.The Food and Drug Administration of the United States lists positive dechallenge reactions (an adverse event which disappears on withdrawal of the medication) as well as negative (an adverse event which continues after withdrawal), as well as ...
The black triangle also highlights the need for surveillance of any Adverse Drug Reactions (ADRs) that might arise from the use of a new medication. The Medicines and Healthcare products Regulatory Agency (MHRA) encourage anyone to voluntarily report ADRs (however minor) via the Yellow Card Scheme to gather more information and gain more ...
This is the template test cases page for the sandbox of Template:Infobox drug to update the examples. If there are many examples of a complicated template, later ones may break due to limits in MediaWiki; see the HTML comment "NewPP limit report" in the rendered page. You can also use Special:ExpandTemplates to examine the results of template uses. You can test how this page looks in the ...
A risk management plan is a documented plan that describes the risks (adverse drug reactions and potential adverse reactions) associated with the use of a drug and how they are being handled (warning on drug label or on packet inserts of possible side effects which if observed should cause the patient to inform/see his physician and/or ...
Risk Evaluation and Mitigation Strategies (REMS) is a program of the US Food and Drug Administration for the monitoring of medications with a high potential for serious adverse effects. REMS applies only to specific prescription drugs, but can apply to brand name or generic drugs. [1] The REMS program was formalized in 2007.